Bharat Parenterals Ltd
Bharat Parenterals Q1 FY27: Revenue ₹93.7 Cr, Net loss ₹3.6 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #10 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Bharat Parenterals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
Revenue & Sales Performance
- Consolidated Revenue Q1 FY27: ₹93.7 Cr, down 19.2% YoY from ₹116.0 Cr in Q1 FY26.
- BPL Standalone Revenue Q1 FY27: ₹55.5 Cr, down 41.2% YoY from ₹94.4 Cr in Q1 FY26.
- Innoxel Revenue Q1 FY27: ₹21.4 Cr, up 165% YoY from ₹8.1 Cr in Q1 FY26.
- Varenyam Healthcare Revenue Q1 FY27: ₹25.1 Cr, up 52.2% YoY from ₹16.5 Cr in Q1 FY26.
- Indian market volume growth cited at +0.6% (Page 9).
- Outlook:
- BPL Standalone growth guided at 10-15% YoY for FY27.
- Innoxel revenue growth 35-45% YoY targeted; commercial CMO supply starts Q2 FY27.
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Varenyam Bio Lifesciences (100% subsidiary)
- Project budget: ₹160 Cr
- CWIP: ₹33.22 Cr (20.8% of budget) as of Q1 FY27
- Civil work: 50% complete; equipment ordered 40%
- Planned lines: 2 oncology, 1 injectable with lyophilisation, 1 oral liquid
- Commissioning targeted: September 2027
- Line validation: March 2028
- First EU-GMP filing: Q1 FY29
- First commercial supply: Q4 FY29
- Facility location: Vadodara (under development)
- Innoxel Lifesciences
- Cumulative capex: ~₹250 Cr originally guided; ₹216.65 Cr spent by FY27 start
- FY26 capex: ₹22.83 Cr
- Lines validated: 4 cumulative
- First commercial CMO supply: Starts Q2 FY27
- BPL Standalone
- Capex FY26: ₹12.84 Cr; FY27 plan: ₹15 Cr
- QC lab expansion, robotic PFS filling, track & trace, roller compactor, ORABS and water system upgrades ongoing
- Overall
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Bharat Parenterals Limited standalone order book as of Q1 FY27: ₹171 Cr
- Domestic tenders: ₹119 Cr
- Exports: ₹33 Cr
- International tenders: ₹20 Cr
- This covers approximately 80–85% of the revenue needed over the remaining nine months to meet guided FY27 revenue.
- The order book relates to the ₹210 Cr institutional order's opening tranche.
- Domestic tender order book alone (single-state tenders) runs ₹880–965 Cr, indicating a larger market opportunity beyond current orders.
2 more points from Bharat Parenterals Ltd's call on order book
Create a free account to keep reading this call
Bharat Parenterals Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Bio Lifesciences (100% subsidiary) - Project budget: ₹160 Cr - CWIP: ₹33.22 Cr (20.8% of budget) as of Q1 FY27 - Civil work: 50% complete; equipment ordered 40% - Planned lines: 2 o
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.